C07K 14/521
Chemokines
Official title: {Chemokines}
C07K14/521 (Chemokines) appears on 667 US grants and 915 published applications in this corpus.
Search patents in C07K- Granted patents
- 667
- Published applications
- 915
- Assignees
- 474
- Inventors
- 1,675
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 6 | 0 |
| 1994 | 6 | 0 |
| 1995 | 11 | 0 |
| 1996 | 9 | 0 |
| 1997 | 17 | 0 |
| 1998 | 31 | 0 |
| 1999 | 37 | 0 |
| 2000 | 33 | 0 |
| 2001 | 14 | 4 |
| 2002 | 30 | 45 |
| 2003 | 22 | 83 |
| 2004 | 25 | 37 |
| 2005 | 20 | 35 |
| 2006 | 28 | 40 |
| 2007 | 23 | 35 |
| 2008 | 23 | 33 |
| 2009 | 12 | 32 |
| 2010 | 22 | 24 |
| 2011 | 17 | 35 |
| 2012 | 18 | 27 |
| 2013 | 18 | 24 |
| 2014 | 17 | 26 |
| 2015 | 17 | 19 |
| 2016 | 14 | 25 |
| 2017 | 12 | 23 |
| 2018 | 13 | 31 |
| 2019 | 15 | 39 |
| 2020 | 29 | 45 |
| 2021 | 18 | 32 |
| 2022 | 24 | 43 |
| 2023 | 21 | 44 |
| 2024 | 11 | 49 |
| 2025 | 27 | 45 |
| 2026 | 15 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell8 Sep 2026US 12,729,372 B2Changen Therapeutics (Shanghai) Co., Ltd.
- Methods for reducing elevated glucose levels11 Aug 2026US 12,703,856 B2SDF BioPharma Inc.
- Methods and compositions for treating cancer with von Willebrand factor peptide linked to immunotherapeutic antibodies11 Aug 2026US 12,706,227 B2The University of Chicago
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- Recombinant aav as an immune adjuvant24 Sep 2026US 2026/0285929 A1University of Florida Research Foundation, Inc.
- Nanostructured proteins and uses thereof10 Sep 2026US 2026/0265317 A1
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Adenovirus armed with bispecific t cell engager20 Aug 2026US 2026/0242505 A1Akamis Bio Limited
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
Most cited
By later US patents
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Therapeutic interleukin-2-antibody based fusion proteins170US 5,314,995 AOncogen · 1994
- Modified PF4 compositions and methods of use156US 5,112,946 ARepligen Corporation · 1992
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)104US 4,603,106 AThe Rockefeller University · 1986
- Bispecific antibody and chemokine receptor constructs97US 6,723,538 B2Micromet AG · 2004